Systemic sclerosis is a complex autoimmune disease characterized by inflammation, fibrosis, and microvascular dysfunction, with oxidative stress playing a significant role in its pathophysiology. Bilirubin, as an endogenous antioxidant, may represent a potential protective factor; therefore, the aim of this study was to investigate its association with markers of oxidative stress and inflammation in patients with systemic sclerosis.
Our retrospective study included 38 patients with systemic sclerosis for whom laboratory parameters were analyzed, including bilirubin, the oxidative stress marker d-ROM, antioxidant capacity (PAT), oxidative stress index (OSI), and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Statistical analysis included descriptive statistics, normality testing, and correlation analysis. Multiple linear regression was performed to assess the independent associations of selected variables with bilirubin serum levels.
The results did not demonstrate statistically significant associations between bilirubin and the studied parameters of oxidative stress, antioxidant capacity, or inflammation. In contrast, a statistically significant positive correlation was found between the oxidative stress index (OSI) and CRP, as well as between OSI and ESR, indicating an association between oxidative stress and systemic inflammation in patients with systemic sclerosis. A negative association between serum bilirubin and erythrocyte sedimentation rate was observed, although it did not reach statistical significance. Multiple linear regression analysis showed that neither CRP nor OSI were independent predictors of bilirubin levels.
Based on these findings, bilirubin does not appear to be a reliable standalone biomarker of oxidative stress or inflammation in our group of patients with systemic sclerosis; rather, its role is likely more complex and indirect. The results also highlight the close interplay between oxidative stress and inflammation, which is essential for understanding the pathophysiology of the disease.
Further studies with larger sample sizes and a broader range of biomarkers are needed to better define the role of bilirubin and its potential clinical relevance.
|